Alexander Eggermont, MD, PhD, of Gustave Roussy, discusses final overall survival findings on ipilimumab vs placebo after complete resection of stage III melanoma. (Abstract LBA2)
Susana N. Banerjee, PhD, MBBS, of The Royal Marsden NHS Foundation Trust, discusses phase II findings on abiraterone in patients with recurrent epithelial ovarian cancer. (Abstract LBA33)
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how long-term study results showed no survival benefit in men with ogliometastatic prostate cancer. (Abstract 720PD)
Alain Ravaud, MD, PhD, of Bordeaux University Hospital, discusses phase III findings on sunitinib vs placebo as adjuvant treatment for high-risk renal cell carcinoma after nephrectomy. (Abstract LBA11)
Sian A. Pugh, MBBS, of Southampton University Hospital, discusses 6 to 12-year findings on the scheduled use of the CEA tumor marker and CT follow-up to detect recurrence of colorectal cancer. (Abstract 453O)
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on cabozantinib vs sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor and intermediate risk. (Abstract LBA30) Follow him on Twitter: @DrChoueiri
